Register now to get industry insights from a host of expert industry speakers
Enhertu is currently approved for HER2-low metastatic breast cancer in over 30 countries
The US company will initiate a phase 2 study to evaluate the vaccine candidate
The development follows the Group’s acquisition of Hutano Diagnostics
Trial results show that the software boosts breast cancer detection by 20%